Author

Jacques Zimmer

Luxembourg Institute of HealthORCID 0000-0002-7118-6944Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2

Frequent Co-Authors

Gilles Iserentant· 2 shared Jean-Yves Servais· 2 shared Anaïs OudiniD· 1 shared Anna GolebiewskaiD· 1 shared Aubin PitiotiD· 1 shared Bianca Brandus· 1 shared Camille RoliniD· 1 shared Carole Seguin-Devaux· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Gilles Iserentant

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Strength in Unity: a Dual Strategy to Restore NK Cell Cytotoxicity against Pancreatic Ductal Adenocarcinoma

Camille Rolin, Aubin Pitiot, Gilles Iserentant, Anaïs Oudin, Jean-Yves Servais, Victoria El‐Khoury, Vanessa Barthelemy, Céline Hoffmann, Anna Golebiewska, Yong-Jun Kwon, Jacques Zimmer, Carole Seguin‐Devaux

This study develops and tests a dual strategy using NaMiX and TriKE to enhance NK cell cytotoxicity against PDAC, showing improved tumor cell killing in vitro and in humanized mouse models.

bioRxiv · Feb 11, 2026 · PreprintImmunology

Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy

Carole Seguin-Devaux, Bianca Brandus, Jean-Marc Plesseria, Gilles Iserentant, Jean-Yves Servais, Georgia Kanli, Iris Behrmann, Jacques Zimmer, Jacques H M Cohen, Xavier Dervillez

This study develops and tests CoMiX immunotherapeutics that activate complement to kill HER2-positive breast cancer cells, showing significant tumor growth inhibition in xenograft models.

bioRxiv · Feb 2, 2024 · PreprintImmunology